{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:47:26Z","timestamp":1790099246395,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1067\/mhj.2002.129969","type":"journal-article","created":{"date-parts":[[2002,12,27]],"date-time":"2002-12-27T17:26:00Z","timestamp":1041009960000},"page":"S2-S7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"S","title":["Aldosterone: Cardiovascular assault"],"prefix":"10.1067","volume":"144","author":[{"given":"Allan D.","family":"Struthers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mhj.2002.129969_bib1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129969_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129969_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"issue":"F Suppl","key":"10.1067\/mhj.2002.129969_bib4","first-page":"13","article-title":"The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases","volume":"11","author":"Liao","year":"1995","journal-title":"Can J Cardiol"},{"key":"10.1067\/mhj.2002.129969_bib5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.129969_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"10.1067\/mhj.2002.129969_bib7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.129969_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1472-8206.2000.tb00439.x","article-title":"Pathophysiology of aldosterone and its antagonists","volume":"14","author":"Struthers","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1067\/mhj.2002.129969_bib9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129969_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.129969_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","article-title":"Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta","volume":"290","author":"Ikeda","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1067\/mhj.2002.129969_bib12","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1067\/mhj.2002.129969_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11906-000-0017-z","article-title":"Aldosterone and vascular damage","volume":"2","author":"Duprez","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1067\/mhj.2002.129969_bib14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/014107680109400803","article-title":"Aldosterone as a determinant of cardiovascular and renal dysfunction","volume":"94","author":"Epstein","year":"2001","journal-title":"J R Soc Med"},{"key":"10.1067\/mhj.2002.129969_bib15","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production","volume":"85","author":"Brown","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1067\/mhj.2002.129969_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129969_bib17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"10.1067\/mhj.2002.129969_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129969_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129969_bib20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J Mol Cell Cardiol"},{"key":"10.1067\/mhj.2002.129969_bib21","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1067\/mhj.2002.129969_bib22","first-page":"479","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"38","author":"Rocha","year":"2001","journal-title":"Hypertension"},{"key":"10.1067\/mhj.2002.129969_bib23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0002-9149(91)90410-M","article-title":"Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension","volume":"68","author":"Bauwens","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2002.129969_bib24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis","volume":"12","author":"Sato","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1067\/mhj.2002.129969_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","article-title":"Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension","volume":"22","author":"Sato","year":"1999","journal-title":"Hypertens Res"},{"key":"10.1067\/mhj.2002.129969_bib26","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.129969_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1067\/mhj.2002.129969_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0002-9149(93)90239-9","article-title":"Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension","volume":"71","author":"Brilla","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2002.129969_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF01906668","article-title":"Connective tissue content and myocardial stiffness in pressure overload hypertrophy: a combined study of morphologic, morphometric, biochemical, and mechanical parameters","volume":"78","author":"Thiedemann","year":"1983","journal-title":"Basic Res Cardiol"},{"key":"10.1067\/mhj.2002.129969_bib30","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.129969_bib31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11906-000-0041-z","article-title":"The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure","volume":"2","author":"Hameedi","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1067\/mhj.2002.129969_bib32","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2002.129969_bib33","first-page":"1783","article-title":"Aldosterone action","author":"Mortensen","year":"2001"},{"key":"10.1067\/mhj.2002.129969_bib34","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.160.16.2429","article-title":"New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice","volume":"160","author":"Cohn","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1067\/mhj.2002.129969_bib35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.98.12.1198","article-title":"Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men","volume":"98","author":"Ascherio","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.129969_bib36","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/01.CIR.98.15.1510","article-title":"Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-HEART)","volume":"98","author":"Nolan","year":"1998","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.129969_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-115-2-77","article-title":"Potassium depletion exacerbates essential hypertension","volume":"115","author":"Krishna","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1067\/mhj.2002.129969_bib38","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.1997.03540440058033","article-title":"Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials","volume":"277","author":"Whelton","year":"1997","journal-title":"JAMA"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870302002107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870302002107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:49:20Z","timestamp":1757566160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870302002107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["S0002870302002107"],"URL":"https:\/\/doi.org\/10.1067\/mhj.2002.129969","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone: Cardiovascular assault","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1067\/mhj.2002.129969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}